☰

Gerard Joseph Marek

Affiliations: 
Yale University, New Haven, CT 
Area:
Prefrontal cortex and 5-HT2A receptor/glutamate interactions
Google:
"Gerard Marek"
Mean distance: (not calculated yet)
 
Tree Publications Grants Similar researchers PubMed Report error

Parents

Sign in to add mentor
Lewis Stanford Seiden grad student 1982-1989 Chicago
George K. Aghajanian post-doc 1993-2001 Yale School of Medicine
 (Post-doc 93-96 and colleague 96-2001)

Children

Sign in to add trainee

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Klein AK, Austin EW, Cunningham MJ, et al. (2024) GM-1020: a novel, orally bioavailable NMDA receptor antagonist with rapid and robust antidepressant-like effects at well-tolerated doses in rodents. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Marek GJ, Salek AA. (2020) Extending the specificity of differential-reinforcement-of-low rate 72-s (DRL 72-s) behavior for screening antidepressant-like effects of glutamatergic clinically validated anxiolytic or antidepressant drugs in rats. The Journal of Pharmacology and Experimental Therapeutics
Marek GJ, Ramos BP. (2018) β-Adrenergic Receptor Activation Suppresses the Rat Phenethylamine Hallucinogen-Induced Head Twitch Response: Hallucinogen-Induced Excitatory Post-synaptic Potentials as a Potential Substrate. Frontiers in Pharmacology. 9: 89
Marek GJ. (2017) Interactions of Hallucinogens with the Glutamatergic System: Permissive Network Effects Mediated Through Cortical Layer V Pyramidal Neurons. Current Topics in Behavioral Neurosciences
Marek GJ. (2015) When is a Proof-of-Concept (POC) not a POC? Pomaglumetad (LY2140023) as a Case Study for Antipsychotic Efficacy. Current Pharmaceutical Design. 21: 3788-96
Wright RA, Johnson BG, Zhang C, et al. (2013) CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [³H]LY459477 autoradiography. Neuropharmacology. 66: 89-98
Marek GJ. (2012) Activation of adenosine₁ receptors induces antidepressant-like, anti-impulsive effects on differential reinforcement of low-rate 72-s behavior in rats. The Journal of Pharmacology and Experimental Therapeutics. 341: 564-70
Fell MJ, Witkin JM, Falcone JF, et al. (2011) N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. The Journal of Pharmacology and Experimental Therapeutics. 336: 165-77
Nikiforuk A, Popik P, Drescher KU, et al. (2010) Effects of a positive allosteric modulator of group II metabotropic glutamate receptors, LY487379, on cognitive flexibility and impulsive-like responding in rats. The Journal of Pharmacology and Experimental Therapeutics. 335: 665-73
Mezler M, Geneste H, Gault L, et al. (2010) LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Current Opinion in Investigational Drugs (London, England : 2000). 11: 833-45
See more...